Pay in 4 interest-free payments of $7.23 Learn more
Ships within 48 hours · Estimated delivery Sep 23 - Sep 28
Scand J Gastroenterol (1979) 14(2):2057
Our experienced providers will work closely with you to develop a customized treatment plan, monitor your progress, and ensure your safety every step of the way
Bridons research contributions include: Development of Drug Affinity Complex (DAC) technology for albumin binding and peptide half-life extension Identification and characterization of CJC-1295 as a long-lasting GRF analog with sustained growth hormone-releasing properties Pioneering work on maleimido-derivatized GHRH analogs and their bioconjugation to serum albumin Demonstration of 4-fold increase in growth hormone area-under-curve with optimized CJC-1295 formulation versus native GHRH Extensive in vitro and in vivo pharmacological characterization in rat and human models His 2005 publication in Endocrinology titled Human Growth Hormone-Releasing Factor (hGRF)1-29-Albumin Bioconjugates Activate the GRF Receptor on the Anterior Pituitary in Rats: Identification of CJC-1295 as a Long-Lasting GRF Analog remains the foundational reference for CJC-1295 research, establishing the peptides mechanism of action and pharmacokinetic profile that enabled subsequent clinical investigation
Each person responds differently to this slowing effect
US$ 25.89
.png)
US$ 24.08
US$ 21.98
US$ 22.75
US$ 20.32
US$ 21.81
US$ 29.19
US$ 26.72
